PDCD1 and neoplasm: Importantly, only CD8 T cell depletion completely abrogated the anti-tumor efficacy of the triple PD-1/LAG-3/CBL-B blockade combination both in terms of survival (Fig. 7B) and tumor growth (Fig. 7C,D).